knowledge -WSS

knowledge

author：focus 2025-09-30 16:27:56 - browse：9

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Medicare reduced heart disease by changing how it pays doctors

WSS

Review: 'Barbie' will hit you like a shot in the heart

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

New rules on organ donation and transplantation 'will bring chaos'

How artificial intelligence is being used to detect, treat cancer

New rules on organ donation and transplantation 'will bring chaos'

entertainment

knowledge

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Will.i.am, Britney Spears release new single, 'Mind Your Business'

As demand for Covid shots wanes, Moderna seeks its next success

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

What does generative AI mean for health care? We asked experts

Beam Therapeutics to lay off 20% of its staff, re

The high cost of giving birth even with insurance

Russian special forces kill a gunman who broke into a private house near Moscow

As demand for Covid shots wanes, Moderna seeks its next success

STAT Summit: GSK CEO on pharma giant's new direction

entertainment

Will Ozempic

FDA struggles to regulate food additives, sometimes for decades

Russian special forces kill a gunman who broke into a private house near Moscow

White House launches permanent pandemic office

The EU Joint Clinical Assessment needs to live up to its promise

7 of the most gruesome medical devices in history

knowledge

knowledge

entertainment

Wikipedia